IOVA Iovance Biotherapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:51
Jul 17
Jul 17
The author highlights IOVA's FDA-approved melanoma treatment as a resilient asset but does not state a personal position or forward directional call.
20:31
Jul 15
Jul 15
The author notes uncertainty about whether the therapy mentioned in the parent context was from IOVA, advising continued monitoring without taking a directional position.
LOW
19:29
Jul 15
Jul 15
Buy $IOVA based on approved TIL therapy for melanoma, promising upcoming solid tumor data (NSCLC), and high M&A attractiveness.
HIGH
16:55
Jul 02
Jul 02
Speaker replies with ticker and handshake emoji, implying agreement with biotech longs but no mechanism or reason.
LOW
16:34
Jun 29
Jun 29
Author discloses current high-conviction long position in IOVA, citing ongoing re-rating with near-term momentum and significant upside potential.
MED
15:09
Jun 23
Jun 23
Buy IOVA as competitive landscape clears after two TIL therapy rivals miss study endpoints; near-term NSCLC data catalyst and M&A candidacy provide additional upside, with author citing high conviction in TIL therapy as a potential cure for metastatic solid tumors.
MED
01:18
Jun 22
Jun 22
Author praises IOVA's TIL therapy as a promising platform but expresses skepticism about achieving complete cures, making cancer a chronic disease instead.
LOW
10:59
Jun 18
Jun 18
Mentions IOVA as a 2-3 year hold, but no directional thesis or catalyst provided.
LOW
10:44
Jun 18
Jun 18
Buy IOVA as part of an AI-augmented biotech basket; author explicitly names it as one of their personal bets on the AI-meets-biology convergence theme.
MED
16:22
Jun 05
Jun 05
Buy healthcare/biotech names like IOVA as recession-resilient demand insulates the sector from a broader equity correction driven by crowded tech unwinds; author cites IOVA as a specific example of the thesis playing out.
MED
19:30
Jun 04
Jun 04
Buy IOVA on a multi-catalyst thesis: clinical efficacy in solid tumors supports expanding label indications, while buyout potential provides a valuation floor and upside optionality.
MED
19:23
Jun 04
Jun 04
Author discloses a large existing long position in IOVA via spot and call options entered near $3.60, indicating strong bullish conviction following a positive conference meeting.
MED
19:15
Jun 04
Jun 04
Buy IOVA; cell therapy TIL data from Jefferies call and strong financials indicate high conviction in the company's prospects.
HIGH
16:56
Jun 04
Jun 04
Author is waiting for a Jefferies conference call about Iovance Biotherapeutics and posts a poodle photo, not expressing any trade position.
LOW
15:42
Jun 04
Jun 04
Author notes IOVA as a cell therapy stock moving in the biotech sector, no directional view.
LOW
14:55
Jun 04
Jun 04
Author evaluates three biotech tickers as potential long-term holds depending on clinical data, explicitly ruling out ABSI, but offers no personal position or forward call.
LOW
14:50
Jun 04
Jun 04
Author reiterates a prior bullish biotech thesis from research discord but provides no current position disclosure or forward directional call in the tweet itself.
21:54
Jun 03
Jun 03
Buy IOVA into back-to-back catalysts — Australian TGA approval of Amtagvi in melanoma already in hand, with a Jefferies presentation tomorrow expected to show favorable early NSCLC cohort data, potentially expanding the addressable indication.
MED
00:56
Jun 02
Jun 02
Author explicitly says ABSI, ABCL, and IOVA are their bets on the digital biology narrative, which they expects to run hard.
MED
12:10
Jun 01
Jun 01
Buy IOVA on FDA IND approval for IOV-5001 targeting colorectal and breast cancers — two of the highest-prevalence tumor types globally — which meaningfully expands the addressable market for TIL therapy if trial data is positive.
MED
23:36
May 31
May 31
Buy IOVA ahead of upcoming TIL (tumor-infiltrating lymphocyte) therapy clinical data readout in NSCLC; speaker frames this as a personal directional bet on the cell therapy catalyst.
MED
18:12
May 29
May 29
Buy IOVA ahead of next week's ASCO presentation of NSCLC small-population durability data; author frames this as part of a broader "digital biology" rerating that is "only just beginning," suggesting upside catalyst from clinical readout.
MED
00:34
May 29
May 29
Buy IOVA for its unique FDA-approved TIL therapy, upcoming ASCO data, strong patent protection, and high probability of acquisition given scalability limitations and long cash runway.
MED
10:30
May 28
May 28
Buy IOVA as its TIL production patent protection (20+ years vs. 7–12yr for traditional biologics) creates a durable competitive moat; as the only FDA-approved TIL therapy, this patent advantage underpins a structurally superior long-term revenue base.
MED
20:48
May 27
May 27
First-hand account of IOVA tumor board presentations at top-10 oncology centers showing ~50% response rate in stage IV refractory pancreatic/cholangiocarcinoma, with deep durable responses in half of responders — substantive clinical data point.
MED
18:38
May 27
May 27
Buy IOVA — author has taken a large equity and options position at $3.60–$3.90, citing TIL (tumor-infiltrating lymphocyte) therapy as one of the best potential curative approaches in its category, with full DD forthcoming.
HIGH
20:18
May 23
May 23
IOVA presented TIL therapy data (with pembrolizumab) in stage IV refractory pancreatic and cholangiocarcinoma patients at a tumor board; partial response signal noted.
LOW
13:09
Apr 27
Apr 27
Adam May boasts a strong short-selling track record with past wins on NTLA, HIMS, VKTX, and IOVA, and expresses a forward-looking bearish view on ORKA.
HIGH
07:10
Apr 07
Apr 07
The author recommends buying IOVA stock on a price dip based on a thesis of sustained multi-year growth potential.
HIGH
About IOVA Analyst Coverage
Buzzberg tracks IOVA (Iovance Biotherapeutics, Inc.) across 3 sources. 16 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (55%). 29 total trade ideas tracked. Past 7 days: 1 bullish, 2 watch. Latest voices: CryptoCondom, crypto_condom, @crypto_condom.